MAPP BIOPHARMACEUTICAL, INC.
- SAN DIEGO, CA 92121-3823
- mappbio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
MAPP BIOPHARMACEUTICAL, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About MAPP BIOPHARMACEUTICAL, INC.
- Headquarters
- SAN DIEGO, CA 92121-3823
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIM9V9QTHR1H28
- CAGE417U0
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 30 awards
- Total awarded
- $28,308,794
- By phase
- SBIR Phase I: 18
- SBIR Phase II: 9
- STTR Phase I: 2
- STTR Phase II: 1
- By agency
- Department of Health and Human Services: 26
- Department of Defense: 4
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 2
- 2020: 2
- 2018: 3
- 2017: 4
- 2016: 1
- 2015: 2
- 2014: 4
- 2012: 1
- 2011: 1
- 2010: 1
- 2009: 1
- 2008: 2
- 2007: 2
- 2006: 2
- 2005: 1
- 2004: 1
Awards (most recent first)
Development of highly potent human monoclonal for RSV immunoprophylaxis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $993,353
Sep 24, 2025 – Aug 31, 2028
- Active
Solicitation PAR23-219 (2023) · Topic NIAID
A Novel Cost-Effective Multispecific Therapeutic for Dengue
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $294,583
Jun 9, 2025 – May 31, 2026
Solicitation PA24-245 (2024) · Topic NIAID
Marburg Virus Prophylactic Medical Countermeasure
STTR Phase II · Department of Defense (Office for Chemical and Biological Defense) · 2020 · $999,034
Jul 28, 2020 – Jul 28, 2022
Solicitation 18.A (2018) · Topic CBD18A-002 · Research partner: Mapp Biopharmaceutical
Development of highly potent human monoclonal for RSV immuno-prophylaxis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,747,713
Jul 2, 2020 – Jun 30, 2023
Solicitation PA19-272 (2019) · Topic NIAID
Marburg Virus Prophylactic Medical Countermeasure
STTR Phase I · Department of Defense (Office for Chemical and Biological Defense) · 2018 · $149,999
Sep 27, 2018 – Mar 27, 2019
Solicitation 2018.0 (2018) · Topic CBD18A-002 · Research partner: University of Texas Medical Branch
Post-exposure immunotherapy for ricin exposure
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $298,015
Jun 29, 2018 – May 31, 2020
Solicitation PA17-302 (2017) · Topic NIAID
Development of highly potent human monoclonals for RSV immunoprophylaxis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $600,000
Jan 15, 2018 – Jun 30, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Direct Sequencing of Antibodies of the Influenza Immune Response
SBIR Phase I · Department of Health and Human Services (Centers for Disease Control and Prevention) · 2017 · $225,000
Sep 1, 2017 – Mar 31, 2018
Solicitation PA16-302 (2016) · Topic NCIRD
MR191_An Immunoprotectantfor Marburg Virus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $3,000,000
Jul 1, 2017 – Jun 30, 2020
Solicitation PAR16-027 (2016) · Topic NIAID
Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life
SBIR Phase II · Department of Defense (Army) · 2017 · $999,928
Jun 22, 2017 – Jun 21, 2018
Solicitation 2014.1 (2014) · Topic A14-044
Direct sequencing of serum antibodies after infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $255,046
Feb 1, 2017 – Oct 31, 2018
Solicitation PA15-269 (2015) · Topic NIAID
Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $240,221
Aug 1, 2016 – Apr 30, 2017
Solicitation PA15-269 (2016) · Topic NIAID
Pseudomonas antibodies with designed glycans
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $228,758
Jan 5, 2015 – Dec 31, 2016
Solicitation PA14-071 (2015) · Topic NIAID
Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life
SBIR Phase I · Department of Defense (Army) · 2015 · $149,877
Dec 11, 2014 – May 26, 2016
Solicitation 2014.1 (2014) · Topic A14-044
An SEB Immunoprotectant
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $2,306,794
Aug 20, 2014 – Jul 31, 2018
Solicitation PA10-123 (2010) · Topic R
A human monoclonal for RSV prophylaxis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $600,000
Jul 1, 2014 – Jun 30, 2016
Solicitation PA10-123 (2015) · Topic NIAID
An Immunoprotectant for Marburg Virus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $2,999,994
Jul 1, 2014 – Jun 30, 2017
Solicitation PA10-123 (2016) · Topic R
Novel Immunotherapy for Brain Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $224,988
Solicitation PA14-071 (2014) · Topic NCI · Research partner: Stub
A Monoclonal Cocktail for CDI
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $299,986
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
A Monoclonal Antibody Immunoprotectant for Ebola Virus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $3,000,000
Solicitation PA10-123 (2011) · Topic NIAID · Research partner: Stub
Development of a monoclonal immunoprotectant for ricin
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $600,000
Solicitation PHS2010-2 (2010) · Topic NIAID
An Immunoprotectant for Marburg Virus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $524,876
Solicitation PHS2009-2 (2009)
Monoclonal Antibody SEB Immunoprotectant
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $599,821
Solicitation PHS2007-2 (2008)
Monoclonal Antibodies for Alzheimer's Immunotherapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2008 · $2,815,180
Solicitation PHS2007-2 (2008)
A Monoclonal Antibody Immunoprotectant for Ebola Virus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $270,810
Solicitation year 2007
Showing the 25 most recent of 30 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
- 325413Title not in the curated listSmall business under this code’s size standard
SAM.gov reports this entity as small under 2 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with MAPP BIOPHARMACEUTICAL, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.